Abstract 1191P
Background
Thyroid transcription factor-1 (TTF-1), is expressed in thyroid and lung tissue. TTF-1, assessed by immunohistochemistry (IHC), is a specific biomarker for lung adenocarcinoma, and is commonly used to confirm the pulmonary origin of neuroendocrine tumors (NET), as well. The majority of the available data suggest that TTF-1 is a favourable prognostic biomarker for lung adenocarcinomas, whereas its role in lung NET is controversial.
Methods
A multicenter retrospective study, including 155 Lung NET, all surgically removed, all with available IHC assessment for TTF-1.
Results
Median age was 59.5 years (13–86), N= 58 patients (37.4%) were males, N=40 (25.8%) were smokers, N=31 (20%) were atypical carcinoids, N=85 (54.8%) were centrally-located, N=89 (57.4%) were located in the right lung, N=4 patients (2.6%) presented a TNM stage IV at the diagnosis. Mitotic count was ≥2 per 10 high-power field (HPF) in N=35 cases (22.6%), necrosis was present in N=20 (12.9%). Grade 1 was reported in 103 cases (66.5%), whereas Ki-67 was >20% in N=5 (3.2%). TTF-1 was positive in 78 cases (50.3%), cromogranin A in 139 (89.7%) and synaptophysin in 137 (88.4%), respectively. The most common type of surgery was lobectomy in 91 patients (58.7%). Median overall survival (OS) was 46.9 months (0.6–323), median progression-free survival (PFS) was 39.1 months (0.6–323). Statistically significant associations were found between (i) TTF-1 positivity and female sex (p=0.007), and among (ii) TTF-1 positivity and the absence of necrosis (p=0.018). No other relevant associations were detected between TTF-1 and the remaining clinical or pathological variables.
Conclusions
This study highlights that TTF-1 positivity differs according to sex in lung NET patients, with a more common TTF-1 positive staining in female. Moreover, TTF-1 was associated with the absence of necrosis. These data suggest that TTF-1 could potentially represent a gender-related biomarker in this population. Further analyses are needed to establish the value of this observation, and to determine the value of TTF-1 as prognostic biomarker for lung NET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13